Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term ValueJaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and microvillus inclusion disease (MVID) in the US, EU, and/or Middle East/North Africa regions
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term CatalystsSAN FRANCISCO, CA / ACCESS Newswire / February 13, 2025 / Jaguar Health, Inc. (
NASDAQJAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Tuesday, February 18, 2025 at the Emerging Growth Conference.
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor ConferenceMagdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in late 2025/early 2026
Jaguar Health Reports Third Quarter 2024 Financial ResultsThe combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 million
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTOGastrointestinal disorders are the most frequently reported adverse effects during clinical trials of GLP-1 agonists; GI adverse events usually develop in 40-70% of treated patients, and have been reported in up to 85%
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2025 / Jaguar Health, Inc. (
NASDAQJAGX) ("Jaguar" or the "Company") today announced that, effective January 8, 2025, the Company granted 15,000 restricted stock units (RSUs) to New Employee 1, 15,000 RSUs to New Employee 2, and 45,000 RSUs to New Employee 3.
Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech ShowcaseSAN FRANCISCO, CA / ACCESSWIRE / January 8, 2025 / Jaguar Health, Inc. (
NASDAQJAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside chat on January 13, 2025 at the Lytham Partners 2025 Investor Healthcare Summit and in person on January 14, 2025 at Biotech Showcase.
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation ForumMagdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in 2025
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal DisorderThe study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of MVID and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of first IIT proof-of-concept results potentially in Q1 2025
FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in CholeraWorld Health Organization (WHO) has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's CrofelemerCrofelemer is the subject of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - for the rare disease indications of microvillus inclusion disease (MVID) and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of IIT proof-of-concept results potentially in Q2 2025
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) BeginsThe study is one of five clinical efforts - three IIT proof-of-concept studies and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and/or microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder, in the US, EU, and/or Middle East/North Africa (MENA) regions; availability of IIT proof-of-concept results potentially in Q2 2025
Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth ConferenceSAN FRANCISCO, CA / ACCESSWIRE / November 25, 2024 / Jaguar Health, Inc. (
NASDAQJAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on December 3, 2024 at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference, and present virtually on December 5, 2024 at the Emerging Growth Conference.
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in DogsDiarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar's novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases
